SCHEMBL29401007

SCHEMBL29401007

Cc1c(C)c(S(=O)(=O)NC(=N)NCCC[C@H](NC(=O)OC(C)(C)C)C(=O)O)c(C)c2c1OC(C)(C)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
PLG P00747 3/20 0.34
PLAU P00749 2/20 0.34
F2 P00734 1/20 0.34
ST14 Q9Y5Y6 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
CAPN1 P07384 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
F10 P00742 1/20 0.32
KLKB1 P03952 1/20 0.32
KLK7 P49862 2/20 0.32
KLK5 Q9Y337 2/20 0.32
CTSK P43235 3/20 0.32
CTSS P25774 1/20 0.32
C3AR1 Q16581 1/20 0.31
PPARG P37231 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15407157 1.00 ALDH1A1 (0.39) ALDH1A1TSHRPLGPLAUF2
SCHEMBL29400475 1.00 ALDH1A1 (0.39) ALDH1A1TSHRPLGPLAUF2
SCHEMBL27429599 1.00 ALDH1A1 (0.39) ALDH1A1TSHRPLGPLAUF2
SCHEMBL20561238 1.00 ALDH1A1 (0.39) ALDH1A1TSHRPLGPLAUF2
SCHEMBL16893643 0.98 ALDH1A1 (0.41) ALDH1A1TSHRPLGPLAUF2
SCHEMBL31058628 0.97 ALDH1A1 (0.37) ALDH1A1TSHRPLGPLAUF2
SCHEMBL30918351 0.94 ALDH1A1 (0.35) ALDH1A1TSHRPLGPLAUF2
SCHEMBL17154024 0.94 PLG (0.34) ALDH1A1TSHRPLGPLAUF2
SCHEMBL30918344 0.94 ALDH1A1 (0.35) ALDH1A1TSHRPLGPLAUF2
SCHEMBL31235336 0.93 ALDH1A1 (0.38) ALDH1A1TSHRPLGPLAUF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3934635-B1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF ENSYSCE BIOSCIENCES INC (US) 2026-05-20 EP disclosed
EP-3355885-B1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS INC (US) 2026-02-25 EP disclosed
EP-4692086-A1 ANTICOAGULATION REVERSAL AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shaanxi Micot Pharmaceutical Technology Co., Ltd. (CN) 2026-02-11 EP disclosed
EP-4321524-B1 LIPID AND COMPOSITION SOGO PHARM (JP) 2025-12-10 EP disclosed
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis APICAL MOLECULAR BIOTECH CO., LTD. (TW) 2025-11-11 US disclosed
US-20250326807-A1 CALPROTECTIN BINDING PEPTIDES BUEHLMANN LABORATORIES AG (CH) 2025-10-23 US disclosed
EP-4136063-B1 NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS APICAL MOLECULAR BIOTECH CO LTD (TW) 2025-10-22 EP disclosed
US-20250304645-A1 Prodrugs of GLP-1 Polypeptide and Uses Thereof NOVO NORDISK A/S (DK) 2025-10-02 US disclosed
US-12312621-B2 Reprogramming urokinase into an antibody-recruiting anticancer agent YALE UNIVERSITY (US) 2025-05-27 US disclosed
US-20250161468-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE ELYSIUM THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-3131566-B1 BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF UNIV CALIFORNIA (US) 2022-10-05 EP disclosed
WO-2022185319-A1 UBIQUITIN LIGASE KPC1-PEPTIDE BASED PROTEOLYSIS TARGETING CHIMERAS (PROTAC) AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2022-09-09 WO disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof SIGNATURE THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
WO-2022136366-A1 NOVEL METHOD FOR SYNTHESIZING NCA COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER (ENSCM) (FR) 2022-06-30 WO disclosed
WO-2022133069-A1 PEPTIDOMIMETIC MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. (US) 2022-06-23 WO disclosed
US-20220175699-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF 3I, LP 2022-06-09 US disclosed
US-20220107246-A1 NONCOVALENT TAGS AND RELATED METHODS FOR CYTOSOLIC DELIVERY OF MACROBIOMOLECULES UNIVERSITY OF WASHINGTON (US) 2022-04-07 US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 WO disclosed
US-20220062371-A1 LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2022-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220062371-A1 LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B CTSB, CTSE, CTSV ALDH1A1 2519/4885TSHR 2042/4885PLG 180/4885
US-20250161468-A1 POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE OPRM1, OPRK1, OPRL1 ALDH1A1 292/4885TSHR 4303/4885PLG 728/4885
US-12466784-B2 Analogs of pterostilbene amino acid bearing carbonates for treating a non-alcoholic fatty liver disease and nonalcoholic steatohepatitis FABP1, GLS2, SLC1A5 ALDH1A1 1721/4885TSHR 3419/4885PLG 1425/4885
US-12312621-B2 Reprogramming urokinase into an antibody-recruiting anticancer agent PLAUR, CD47, CD14 ALDH1A1 3594/4885TSHR 1054/4885PLG 10/4885
US-20220175699-A1 COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF ACHE, DNPEP, ACE ALDH1A1 2381/4885TSHR 3098/4885PLG 463/4885
US-11400062-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof ACHE, COMT, CES2 ALDH1A1 795/4885TSHR 3797/4885PLG 443/4885
US-20250304645-A1 Prodrugs of GLP-1 Polypeptide and Uses Thereof GLP1R, IAPP, GCG ALDH1A1 1250/4885TSHR 1690/4885PLG 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.